Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00193141
Other study ID # SCRI GI 23
Secondary ID
Status Completed
Phase Phase 2
First received September 12, 2005
Last updated May 2, 2011
Start date October 1999
Est. completion date July 2007

Study information

Verified date May 2011
Source SCRI Development Innovations, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

In this randomized study, we plan to address the important question of optimum local treatment for patients with localized esophageal cancer. All patients will receive our previously studied neo-adjuvant regimen including paclitaxel, carboplatin, infusional 5-FU, and radiation therapy to 45 Gy. At the completion of neo-adjuvant therapy, patients will be randomized to undergo surgical resection, or to continue radiation to a total dose of 60 Gy, along with one additional course of chemotherapy.


Description:

Upon determination of eligibility, all patients will receive neo-adjuvant therapy with:

Paclitaxel + Carboplatin + 5-Fluorouracil + Radiation

After neo-adjuvant therapy and restaging are completed, patients will be randomized to receive one of two treatments:

- Surgical resection (Arm A)

- Paclitaxel + Carboplatin + Radiation (Arm B)


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date July 2007
Est. primary completion date October 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

To be included in this study, you must meet the following criteria:

- Cancer of the esophagus or gastroesophageal junction confirmed by biopsy (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma) clinical stage I, II, or III.

- Received no previous treatment for esophageal cancer.

- Measurable or evaluable disease

- Able to perform activities of daily living with minimal assistance

- Adequate bone marrow, liver and kidney function

- Be at least 3 weeks from any major surgical procedures.

- Have an indwelling central venous access catheter.

- Patients must be able to understand the nature consent of the study and give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

- Age < 18 years

- History of a prior malignancy within the past 5 years

- History of significant heart disease

- Inoperable on the basis of co-existent medical problems

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Paclitaxel

Carboplatin

5-Fluorouracil


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
SCRI Development Innovations, LLC Bristol-Myers Squibb

References & Publications (1)

Hainsworth JD, Meluch AA, Gray JR, Spigel DR, Meng C, Bearden JD, Hermann R, Greco FA. Concurrent chemoradiation followed by esophageal resection vs chemoradiation alone for localized esophageal cancer. Community Oncology 4:431-439, 2007.

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer
Secondary To compare the toxicity of these two treatment approaches in localized esophageal cancer
Secondary To evaluate the utility of clinical restaging in guiding local therapy (surgical resection vs definitive radiation therapy) following neo-adjuvant treatment
Secondary To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Recruiting NCT06036563 - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Recruiting NCT03941626 - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Phase 1/Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT02988921 - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy N/A
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Recruiting NCT03347630 - Pre-operative MRI of Esophagus Cancer N/A
Recruiting NCT05626309 - Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer N/A
Completed NCT05615129 - Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT04046575 - Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase 1
Recruiting NCT06126406 - Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03467529 - Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Enrolling by invitation NCT06160557 - A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma

External Links